{"id":800376,"date":"2026-04-06T15:18:01","date_gmt":"2026-04-06T15:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=800376"},"modified":"2026-04-06T15:18:01","modified_gmt":"2026-04-06T15:18:01","slug":"bk-virus-infection-clinical-trial-pipeline-expands-as-10-companies-driving-innovation-in-the-therapeutics-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bk-virus-infection-clinical-trial-pipeline-expands-as-10-companies-driving-innovation-in-the-therapeutics-delveinsight_800376.html","title":{"rendered":"BK Virus Infection Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in the Therapeutics | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1775460381.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"BK Virus Infection Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in the Therapeutics | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1775460381.jpg\" alt=\"BK Virus Infection Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in the Therapeutics | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong>BK Virus Infection Pipeline Insight 2026<\/strong>&rdquo; report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in BK Virus Infection pipeline landscape. It covers the <strong>BK Virus Infection pipeline drug <\/strong>profiles, including clinical and nonclinical stage products. It also covers the BK Virus Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Discover the latest drugs and treatment options in the BK Virus Infection Pipeline @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bk-virus-bkv-infection-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">https:\/\/www.delveinsight.com\/sample-request\/bk-virus-bkv-infection-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the BK Virus Infection Pipeline Report<\/strong><\/p>\n<p style=\"text-align: justify;\">&middot; DelveInsight&rsquo;s BK Virus Infection pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Diabetes treatment.<\/p>\n<p style=\"text-align: justify;\">&middot; The leading BK Virus Infection Companies such as <strong><em>SymBio Pharmaceuticals, AlloVir, Memo Therapeutics, Airis Cu<\/em><\/strong> and others.<\/p>\n<p style=\"text-align: justify;\">&middot; Promising BK Virus Infection Pipeline Therapies such as <strong><em>MAU868, Brincidofovir, Posoleucel (ALVR105), Ciclosporin and Mycophenolate-mofetil, Tacrolimus and Mycophenolate-mofetil<\/em><\/strong> and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Stay ahead with the most recent pipeline outlook for BK Virus Infection @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bk-virus-bkv-infection-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">BK Virus Infection Treatment Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>BK Virus Infection Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">BK virus (BKV) is a common opportunistic pathogen in kidney transplant recipients and one of the most challenging causes of allograft dysfunction and loss. This virus was named after a Sudanese kidney transplant recipient with ureteric stenosis who was the first patient to have BKV isolated from the urine. It is a double-stranded circular DNA virus, member of the Betapolyomavirus genus in the Polyomaviridae family.<\/p>\n<p style=\"text-align: justify;\"><strong>BK Virus Infection Emerging Drugs Profile<\/strong><\/p>\n<p style=\"text-align: justify;\">&middot; <strong>ALVR-105: Allovir<\/strong><\/p>\n<p style=\"text-align: justify;\">ALVR 105 (Posoleucel) is a human leukocyte antigen (HLA) matched multi-virus-specific T cell candidate, also known as Viralym-M, developed by AlloVir. Viralym-M is the lead therapeutic candidate in AlloVir&rsquo;s pipeline of allogeneic, off-the-shelf multi-virus specific T-cell therapies designed to treat active virus-associated diseases in immunocompromised patients, including in patients following HSCT, solid organ transplant, or in patients suffering with primary immunodeficiencies, cancer, or HIV. AlloVir has been developing Viralym-M to treat a range of such active virus-associated diseases, including BK hemorrhagic cystitis, cytomegalovirus, adenovirus, Epstein-Barr virus, JC virus and human herpesvirus 6. Currently the drug is in Phase III stage of development for the treatment of BK virus infection.<\/p>\n<p style=\"text-align: justify;\">&middot; <strong>Brincidofovir: SymBio Pharmaceuticals<\/strong><\/p>\n<p style=\"text-align: justify;\">Brincidofovir is an orally available broad-spectrum antiviral agent with activity against various viruses, including BK virus. Studies have indicated that Brincidofovir inhibits BK polyomavirus replication in primary human urothelial cells, suggesting its potential effectiveness in combating BK virus infections. Additionally, Brincidofovir has been used in cases of BK virus-associated nephropathy after allogeneic hematopoietic stem cell transplantation, showing promise in managing these challenging conditions. It is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of BK Virus (BKV) Infection.<\/p>\n<p style=\"text-align: justify;\"><strong>The BK Virus Infection Pipeline Report Provides Insights into<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of BK Virus Infection with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for BK Virus Infection Treatment.<\/li>\n<li>BK Virus Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>BK Virus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the BK Virus Infection market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Explore groundbreaking therapies and clinical trials in the BK Virus Infection Pipeline @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bk-virus-bkv-infection-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">New BK Virus Infection Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>BK Virus Infection Companies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>SymBio Pharmaceuticals, AlloVir, Memo Therapeutics, Airis Cu<\/em><\/strong> and others.<\/p>\n<p style=\"text-align: justify;\"><strong>BK Virus Infection Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">&middot; Oral<\/p>\n<p style=\"text-align: justify;\">&middot; Intravenous<\/p>\n<p style=\"text-align: justify;\">&middot; Subcutaneous<\/p>\n<p style=\"text-align: justify;\">&middot; Parenteral<\/p>\n<p style=\"text-align: justify;\">&middot; Topical<\/p>\n<p style=\"text-align: justify;\"><strong>BK Virus Infection Products have been categorized under various Molecule types such as<\/strong><\/p>\n<p style=\"text-align: justify;\">&middot; Recombinant fusion proteins<\/p>\n<p style=\"text-align: justify;\">&middot; Small molecule<\/p>\n<p style=\"text-align: justify;\">&middot; Monoclonal antibody<\/p>\n<p style=\"text-align: justify;\">&middot; Peptide<\/p>\n<p style=\"text-align: justify;\">&middot; Polymer<\/p>\n<p style=\"text-align: justify;\">&middot; Gene therapy<\/p>\n<p style=\"text-align: justify;\"><strong>Unveil the future of BK Virus Infection Treatment @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bk-virus-bkv-infection-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">BK Virus Infection Market Drivers and Barriers<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the BK Virus Infection Pipeline Report<\/strong><\/p>\n<p style=\"text-align: justify;\">&middot; Coverage- Global<\/p>\n<p style=\"text-align: justify;\">&middot; BK Virus Infection Companies- <strong><em>SymBio Pharmaceuticals, AlloVir, Memo Therapeutics, Airis Cu<\/em><\/strong> and others.<\/p>\n<p style=\"text-align: justify;\">&middot; BK Virus Infection Pipeline Therapies- <strong><em>MAU868, Brincidofovir, Posoleucel (ALVR105), Ciclosporin and Mycophenolate-mofetil, Tacrolimus and Mycophenolate-mofetil<\/em><\/strong> and others.<\/p>\n<p style=\"text-align: justify;\">&middot; BK Virus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/p>\n<p style=\"text-align: justify;\">&middot; BK Virus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/p>\n<p style=\"text-align: justify;\"><strong>Get the latest on BK Virus Infection Therapies and clinical trials @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bk-virus-bkv-infection-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\">BK Virus Infection Companies, Key Products and Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. BK Virus Infection: Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. BK Virus Infection &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">7. In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">8. BK Virus Infection Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">9. Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">10. Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">11. Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">12. Brincidofovir: SymBio Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">13. Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">14. Pre-clinical and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">15. Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">16. Inactive Products<\/p>\n<p style=\"text-align: justify;\">17. BK Virus Infection Key Companies<\/p>\n<p style=\"text-align: justify;\">18. BK Virus Infection Key Products<\/p>\n<p style=\"text-align: justify;\">19. BK Virus Infection- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">20. BK Virus Infection- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">21. BK Virus Infection- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">22. BK Virus Infection Analyst Views<\/p>\n<p style=\"text-align: justify;\">23. BK Virus Infection Key Companies<\/p>\n<p style=\"text-align: justify;\">24. Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=bk-virus-infection-clinical-trial-pipeline-expands-as-10-companies-driving-innovation-in-the-therapeutics-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/bk-virus-bkv-infection-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/bk-virus-bkv-infection-pipeline-insight<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=bk-virus-infection-clinical-trial-pipeline-expands-as-10-companies-driving-innovation-in-the-therapeutics-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s, &ldquo;BK Virus Infection Pipeline Insight 2026&rdquo; report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in BK Virus Infection pipeline landscape. It covers the BK Virus Infection pipeline drug profiles, including clinical and nonclinical stage products. It &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/bk-virus-infection-clinical-trial-pipeline-expands-as-10-companies-driving-innovation-in-the-therapeutics-delveinsight_800376.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,413],"tags":[],"class_list":["post-800376","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/800376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=800376"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/800376\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=800376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=800376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=800376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}